| Year |
Citation |
Score |
| 2021 |
Jeung HC, Delaney R, Aleshin A, Indarte M, Correa RG, Bankston LA, Layng FIAL, Ahmed Z, Wistuba I, Yao Y, Duenas DG, Zhang S, Meuillet EJ, Marassi F, Liddington RC, ... ... Powis G, et al. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. Experimental Cell Research. 112930. PMID 34800542 DOI: 10.1016/j.yexcr.2021.112930 |
0.305 |
|
| 2019 |
Maruggi M, Layng FIAL, Lemos R, Garcia G, James BP, Sevilla M, Soldevila F, Baaten BJG, de Jong PR, Koh MY, Powis G. Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth. Cancer Research. PMID 31585939 DOI: 10.1158/0008-5472.CAN-18-2994 |
0.303 |
|
| 2019 |
Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, ... ... Powis G, et al. An inhibitor of the pleckstrin homology domain of CNK1 selectively blocks the growth of mutant KRAS cells and tumors. Cancer Research. PMID 31040156 DOI: 10.1158/0008-5472.Can-18-2372 |
0.31 |
|
| 2018 |
Campos AD, James B, Jong PD, Lemos R, Marino N, Powis G. Abstract 2428: Redox regulation of β-catenin in colorectal cancer Cancer Research. 78: 2428-2428. DOI: 10.1158/1538-7445.Am2018-2428 |
0.341 |
|
| 2016 |
Grandjean G, De Jong PR, James BP, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby KN, ... Powis G, et al. Definition of a novel feed-forward mechanism for glycolysis-HIF1α signaling in hypoxic tumors highlights adolase A as a therapeutic target. Cancer Research. PMID 27261507 DOI: 10.1158/0008-5472.Can-16-0401 |
0.39 |
|
| 2016 |
Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. PMID 27167191 DOI: 10.18632/Oncotarget.9153 |
0.401 |
|
| 2015 |
Nam S, Chang HR, Jung HR, Gim Y, Kim NY, Grailhe R, Seo HR, Park HS, Balch C, Lee J, Park I, Jung SY, Jeong KC, Powis G, Liang H, et al. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. Cancer Letters. 356: 880-90. PMID 25449779 DOI: 10.1016/J.Canlet.2014.10.038 |
0.358 |
|
| 2015 |
Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Research. 75: 316-29. PMID 25421578 DOI: 10.1158/0008-5472.Can-13-2190 |
0.413 |
|
| 2015 |
Kirkpatrick DL, Indarte M, Scott M, Madrigal A, Grandjean G, Powis G. Abstract 2583: Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth Cancer Research. 75: 2583-2583. DOI: 10.1158/1538-7445.Am2015-2583 |
0.418 |
|
| 2014 |
Nam S, Chang HR, Kim KT, Kook MC, Hong D, Kwon CH, Jung HR, Park HS, Powis G, Liang H, Park T, Kim YH. PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene. 33: 4941-51. PMID 24681952 DOI: 10.1038/Onc.2014.80 |
0.327 |
|
| 2014 |
Chang HR, Nam S, Kook M, Park HS, Jung HR, Gim Y, Liang H, Powis G, Kim YH. Abstract 1781: Identification of focal adhesion and actin cytoskeleton regulation family genes as druggable target for gastric cancer Cancer Research. 74: 1781-1781. DOI: 10.1158/1538-7445.Am2014-1781 |
0.36 |
|
| 2012 |
Koh MY, Powis G. Passing the baton: the HIF switch. Trends in Biochemical Sciences. 37: 364-72. PMID 22818162 DOI: 10.1016/J.Tibs.2012.06.004 |
0.346 |
|
| 2012 |
Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Molecular Cancer Research : McR. 10: 392-400. PMID 22275514 DOI: 10.1158/1541-7786.Mcr-11-0359 |
0.302 |
|
| 2011 |
Kim YH, Coon A, Baker AF, Powis G. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemotherapy and Pharmacology. 68: 405-13. PMID 21069338 DOI: 10.1007/S00280-010-1500-0 |
0.76 |
|
| 2011 |
Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. International Journal of Cancer. 128: 787-96. PMID 20473884 DOI: 10.1002/Ijc.25394 |
0.34 |
|
| 2010 |
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, ... Powis G, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Molecular Cancer Therapeutics. 9: 706-17. PMID 20197390 DOI: 10.1158/1535-7163.Mct-09-0985 |
0.351 |
|
| 2010 |
Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro-Oncology. 12: 559-69. PMID 20156803 DOI: 10.1093/Neuonc/Nop058 |
0.327 |
|
| 2009 |
Koh MY, Spivak-Kroizman TR, Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5945-6. PMID 19789327 DOI: 10.1158/1078-0432.Ccr-09-1650 |
0.339 |
|
| 2009 |
Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Research. 69: 5073-81. PMID 19491272 DOI: 10.1158/0008-5472.Can-08-3839 |
0.317 |
|
| 2007 |
Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Molecular Cancer Therapeutics. 6: 2505-14. PMID 17766839 DOI: 10.1158/1535-7163.MCT-06-0698 |
0.377 |
|
| 2007 |
Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3388-94. PMID 17545547 DOI: 10.1158/1078-0432.Ccr-06-0873 |
0.764 |
|
| 2006 |
Welsh SJ, Koh MY, Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Seminars in Oncology. 33: 486-97. PMID 16890803 DOI: 10.1053/j.seminoncol.2006.04.011 |
0.313 |
|
| 2006 |
Engman L, McNaughton M, Gajewska M, Kumar S, Birmingham A, Powis G. Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds. Anti-Cancer Drugs. 17: 539-44. PMID 16702810 DOI: 10.1097/00001813-200606000-00007 |
0.301 |
|
| 2006 |
Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Molecular Pharmacology. 70: 589-603. PMID 16622074 DOI: 10.1124/Mol.106.025007 |
0.33 |
|
| 2006 |
Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Molecular Cancer Therapeutics. 5: 630-6. PMID 16546977 DOI: 10.1158/1535-7163.Mct-05-0487 |
0.36 |
|
| 2006 |
Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. The Journal of Laboratory and Clinical Medicine. 147: 83-90. PMID 16459166 DOI: 10.1016/J.Lab.2005.09.001 |
0.34 |
|
| 2005 |
Wipf P, Lynch SM, Powis G, Birmingham A, Englund EE. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system. Organic & Biomolecular Chemistry. 3: 3880-2. PMID 16240002 DOI: 10.1039/B510718K |
0.344 |
|
| 2005 |
Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. Nmr in Biomedicine. 18: 430-9. PMID 16206237 DOI: 10.1002/Nbm.977 |
0.344 |
|
| 2005 |
Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (New York, N.Y.). 7: 475-85. PMID 15967100 DOI: 10.1593/Neo.04628 |
0.311 |
|
| 2004 |
Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncology Research. 14: 513-27. PMID 15559765 DOI: 10.3727/0965040042380487 |
0.774 |
|
| 2004 |
Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Archives of Biochemistry and Biophysics. 429: 123-33. PMID 15313215 DOI: 10.1016/J.Abb.2004.04.020 |
0.773 |
|
| 2004 |
Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular Cancer Therapeutics. 3: 763-72. PMID 15252137 |
0.3 |
|
| 2004 |
Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Organic & Biomolecular Chemistry. 2: 1911-20. PMID 15227545 DOI: 10.1039/B405431H |
0.379 |
|
| 2004 |
Mustacich D, Wagner A, Williams R, Bair W, Barbercheck L, Stratton SP, Bhattacharyya AK, Powis G. Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. Carcinogenesis. 25: 1983-9. PMID 15166090 DOI: 10.1093/Carcin/Bgh195 |
0.758 |
|
| 2004 |
Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics. 3: 233-44. PMID 15026543 |
0.301 |
|
| 2003 |
Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Current Cancer Drug Targets. 3: 391-405. PMID 14683498 |
0.314 |
|
| 2003 |
Engman L, Al-Maharik N, McNaughton M, Birmingham A, Powis G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells. Bioorganic & Medicinal Chemistry. 11: 5091-100. PMID 14604673 DOI: 10.1016/J.Bmc.2003.08.021 |
0.425 |
|
| 2003 |
Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. The Journal of Laboratory and Clinical Medicine. 142: 46-51. PMID 12878985 DOI: 10.1016/S0022-2143(03)00068-4 |
0.394 |
|
| 2003 |
Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Molecular Cancer Research : McR. 1: 682-9. PMID 12861054 |
0.631 |
|
| 2003 |
Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. The Journal of Biological Chemistry. 278: 33408-15. PMID 12816947 DOI: 10.1074/Jbc.M211107200 |
0.328 |
|
| 2003 |
Husbeck B, Stringer DE, Gerner EW, Powis G. Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. Biochemical and Biophysical Research Communications. 306: 469-75. PMID 12804587 DOI: 10.1016/S0006-291X(03)00993-8 |
0.795 |
|
| 2003 |
Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Molecular Cancer Therapeutics. 2: 389-99. PMID 12700283 |
0.767 |
|
| 2003 |
Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics. 2: 235-43. PMID 12657718 |
0.311 |
|
| 2003 |
Engman L, Al-Maharik N, McNaughton M, Birmingham A, Powis G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anti-Cancer Drugs. 14: 153-61. PMID 12569302 DOI: 10.1097/00001813-200302000-00009 |
0.302 |
|
| 2003 |
Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Molecular and Cellular Biology. 23: 916-22. PMID 12529397 DOI: 10.1128/Mcb.23.3.916-922.2003 |
0.617 |
|
| 2002 |
Husbeck B, Powis G. The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells. Carcinogenesis. 23: 1625-30. PMID 12376470 DOI: 10.1093/Carcin/23.10.1625 |
0.781 |
|
| 2002 |
Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Research. 62: 5089-95. PMID 12208766 |
0.333 |
|
| 2002 |
Husbeck B, Berggren MI, Powis G. DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences. Advances in Experimental Medicine and Biology. 500: 157-68. PMID 11764930 DOI: 10.1007/978-1-4615-0667-6_21 |
0.799 |
|
| 2001 |
Berggren MI, Husbeck B, Samulitis B, Baker AF, Gallegos A, Powis G. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Archives of Biochemistry and Biophysics. 392: 103-9. PMID 11469800 DOI: 10.1006/Abbi.2001.2435 |
0.779 |
|
| 2001 |
Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annual Review of Biophysics and Biomolecular Structure. 30: 421-55. PMID 11441809 DOI: 10.1146/Annurev.Biophys.30.1.421 |
0.487 |
|
| 2001 |
Xie W, Peng H, Kim DI, Kunkel M, Powis G, Zalkow LH. Structure-activity relationship of aza-steroids as PI-PLC inhibitors. Bioorganic & Medicinal Chemistry. 9: 1073-83. PMID 11377165 DOI: 10.1016/S0968-0896(00)00302-3 |
0.3 |
|
| 2001 |
Rong SB, Hu Y, Enyedy I, Powis G, Meuillet EJ, Wu X, Wang R, Wang S, Kozikowski AP. Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. Journal of Medicinal Chemistry. 44: 898-908. PMID 11300871 DOI: 10.1021/Jm000493I |
0.322 |
|
| 2001 |
Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annual Review of Pharmacology and Toxicology. 41: 261-95. PMID 11264458 DOI: 10.1146/Annurev.Pharmtox.41.1.261 |
0.487 |
|
| 2001 |
Hu Y, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. 3-deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth Bioorganic and Medicinal Chemistry Letters. 11: 173-176. PMID 11206452 DOI: 10.1016/S0960-894X(00)00640-5 |
0.37 |
|
| 2000 |
Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radical Biology & Medicine. 29: 312-22. PMID 11035260 DOI: 10.1016/S0891-5849(00)00313-0 |
0.785 |
|
| 2000 |
Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. Journal of Medicinal Chemistry. 43: 3045-51. PMID 10956212 DOI: 10.1021/Jm000117Y |
0.431 |
|
| 2000 |
Freemerman AJ, Powis G. A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells. Biochemical and Biophysical Research Communications. 274: 136-41. PMID 10903908 DOI: 10.1006/BBRC.2000.3091 |
0.327 |
|
| 2000 |
Xie W, Peng H, Zalkow LH, Li YH, Zhu C, Powis G, Kunkel M. 3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity. Bioorganic & Medicinal Chemistry. 8: 699-706. PMID 10819158 DOI: 10.1016/S0968-0896(00)00014-6 |
0.345 |
|
| 2000 |
Peng H, Xie W, Kim DI, Zalkow LH, Powis G, Otterness DM, Abraham RT. Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase. Bioorganic & Medicinal Chemistry. 8: 299-306. PMID 10722152 DOI: 10.1016/S0968-0896(99)00284-9 |
0.348 |
|
| 2000 |
Baker A, Santos BD, Powis G. Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochemical and Biophysical Research Communications. 268: 78-81. PMID 10652216 DOI: 10.1006/Bbrc.1999.1908 |
0.374 |
|
| 1999 |
Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemotherapy and Pharmacology. 44: 491-7. PMID 10550570 DOI: 10.1007/S002800051123 |
0.361 |
|
| 1999 |
Gasdaska PY, Berggren MM, Berry MJ, Powis G. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. Febs Letters. 442: 105-11. PMID 9923614 DOI: 10.1016/S0014-5793(98)01638-X |
0.35 |
|
| 1999 |
Berggren MM, Mangin JF, Gasdaska JR, Powis G. Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. Biochemical Pharmacology. 57: 187-193. PMID 9890567 DOI: 10.1016/S0006-2952(98)00283-4 |
0.343 |
|
| 1998 |
Powis G, Kirkpatrick DL, Angulo M, Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chemico-Biological Interactions. 23-34. PMID 9679540 DOI: 10.1016/S0009-2797(97)00148-8 |
0.385 |
|
| 1997 |
Dvorakova K, Dorr RT, Gallegos A, McClure T, Powis G. Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. Journal of Chromatography. B, Biomedical Sciences and Applications. 696: 275-81. PMID 9323548 DOI: 10.1016/S0378-4347(97)00261-2 |
0.314 |
|
| 1997 |
Yeates LC, Powis G. The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer Biochemical and Biophysical Research Communications. 238: 66-70. PMID 9299453 DOI: 10.1006/Bbrc.1997.7238 |
0.399 |
|
| 1996 |
Gasdaska JR, Kirkpatrick DL, Montfort W, Kuperus M, Hill SR, Berggren M, Powis G. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73→Ser mutation Biochemical Pharmacology. 52: 1741-1747. PMID 8986137 DOI: 10.1016/S0006-2952(96)00595-3 |
0.387 |
|
| 1996 |
Weichsel A, Gasdaska JR, Powis G, Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure (London, England : 1993). 4: 735-51. PMID 8805557 DOI: 10.1016/S0969-2126(96)00079-2 |
0.359 |
|
| 1995 |
Brunn G, Fauq AH, Chow S, Kozikowski AP, Gallegos A, Powis G. Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity. Cancer Chemotherapy and Pharmacology. 35: 71-9. PMID 7987980 DOI: 10.1007/Bf00686287 |
0.311 |
|
| 1995 |
Powis G, Hill SR, Frew TJ, Sherrill KW. Inhibitors of phospholipid intracellular signaling as antiproliferative agents. Medicinal Research Reviews. 15: 121-38. PMID 7739293 DOI: 10.1002/Med.2610150204 |
0.373 |
|
| 1995 |
Powis G, Berggren M, Gallegos A, Frew T, Hill S, Kozikowski A, Bonjouklian R, Zalkow L, Abraham R, Ashendel C. Advances with phospholipid signalling as a target for anticancer drug development. Acta Biochimica Polonica. 42: 395-403. DOI: 10.18388/Abp.1995_4893 |
0.433 |
|
| 1990 |
Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Beckett GJ, Hayes JD, Wolf CR. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis. 11: 451-8. PMID 2311189 DOI: 10.1093/Carcin/11.3.451 |
0.334 |
|
| 1990 |
Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ, Powis G, Wolf CR. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis. 11: 2163-70. PMID 2265468 DOI: 10.1093/Carcin/11.12.2163 |
0.371 |
|
| 1985 |
Martin WJ, Powis G, Kachel DL. Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells. Journal of Laboratory and Clinical Medicine. 105: 23-29. DOI: 10.5555/Uri:Pii:0022214385900848 |
0.302 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1975 |
Powis G, Boobis AR. Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing edta upon the metabolism of foreign compounds Biochemical Pharmacology. 24: 1771-1776. PMID 823947 DOI: 10.1016/0006-2952(75)90455-4 |
0.3 |
|
| 1975 |
Powis G. The binding of catecholamines to human serum proteins. Biochemical Pharmacology. 24: 707-712. PMID 1125072 DOI: 10.1016/0006-2952(75)90247-6 |
0.298 |
|
| 2009 |
Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Molecular Cancer Therapeutics. 8: 947-58. PMID 19372568 DOI: 10.1158/1535-7163.Mct-08-0981 |
0.297 |
|
| 2004 |
Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Molecular Cancer Therapeutics. 3: 647-54. PMID 15141023 |
0.294 |
|
| 2006 |
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, ... ... Powis G, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. International Journal of Radiation Biology. 82: 699-757. PMID 17118889 DOI: 10.1080/09553000601002324 |
0.294 |
|
| 2009 |
James BP, Staatz WD, Wilkinson ST, Meuillet E, Powis G. Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells. Free Radical Biology & Medicine. 46: 821-7. PMID 19135146 DOI: 10.1016/J.Freeradbiomed.2008.12.012 |
0.292 |
|
| 2000 |
Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Human Pathology. 31: 475-81. PMID 10821495 DOI: 10.1053/HP.2000.6546 |
0.291 |
|
| 2013 |
Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Research. 73: 3235-47. PMID 23633488 DOI: 10.1158/0008-5472.Can-11-1433 |
0.283 |
|
| 1974 |
Clark H, Powis G. Effect of acetone administered in vivo upon hepatic microsomal drug metabolizing activity in the rat. Biochemical Pharmacology. 23: 1015-1019. PMID 4376403 DOI: 10.1016/0006-2952(74)90031-8 |
0.283 |
|
| 1979 |
Powis G. Hepatic microsomal metabolism of epinephrine and adrenochrome by superoxide-dependent and -independent pathways Biochemical Pharmacology. 28: 83-89. PMID 31892 DOI: 10.1016/0006-2952(79)90274-0 |
0.282 |
|
| 2004 |
Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK, Chapman JD, Evans SM, Giaccia AJ, Harris AL, Huang E, Johnson R, Kaelin W, Koch CJ, Maxwell P, ... ... Powis G, et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Research. 64: 3350-6. PMID 15126380 DOI: 10.1158/0008-5472.Can-03-2611 |
0.282 |
|
| 1996 |
Powis G, Briehl M, Oblong J. Redox signalling and the control of cell growth and death. Pharmacology & Therapeutics. 68: 149-73. PMID 8604436 DOI: 10.1016/0163-7258(95)02004-7 |
0.28 |
|
| 1996 |
Gasdaska JR, Gasdaska PY, Gallegos A, Powis G. Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue Genomics. 37: 257-259. PMID 8921404 DOI: 10.1006/Geno.1996.0554 |
0.28 |
|
| 2007 |
Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Current Opinion in Pharmacology. 7: 392-7. PMID 17611157 DOI: 10.1016/j.coph.2007.04.003 |
0.279 |
|
| 2016 |
Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, Park S, Ahn YZ, Huh I, Balch C, Ku JL, Powis G, Park T, Jeong JH, Kim YH. Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer. Oncotarget. PMID 27806312 DOI: 10.18632/oncotarget.12963 |
0.277 |
|
| 2014 |
Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. American Journal of Physiology. Gastrointestinal and Liver Physiology. 306: G48-58. PMID 24177031 DOI: 10.1152/Ajpgi.00234.2013 |
0.276 |
|
| 2014 |
Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, Jung HR, Lemos R, Seo HH, Park HS, Gim Y, Hong D, Huh I, Kim YW, Tan D, ... ... Powis G, et al. HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. PMID 25410163 DOI: 10.1136/Gutjnl-2014-307918 |
0.276 |
|
| 1995 |
Powis G. Signalling pathways as targets for anticancer drug development. Pharmacology & Therapeutics. 62: 57-95. PMID 7991648 DOI: 10.1016/0163-7258(94)90005-1 |
0.276 |
|
| 1999 |
Kanda T, Engman L, Cotgreave IA, Powis G. Novel Water-Soluble Diorganyl Tellurides with Thiol Peroxidase and Antioxidant Activity. The Journal of Organic Chemistry. 64: 8161-8169. PMID 11674732 DOI: 10.1021/Jo990842K |
0.275 |
|
| 2001 |
Berggren MM, Powis G. Alternative splicing is associated with decreased expression of the redox proto-oncogene thioredoxin-1 in human cancers. Archives of Biochemistry and Biophysics. 389: 144-9. PMID 11370665 DOI: 10.1006/ABBI.2001.2325 |
0.275 |
|
| 2008 |
Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, et al. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Molecular Cancer Therapeutics. 7: 2621-32. PMID 18790745 DOI: 10.1158/1535-7163.Mct-07-2276 |
0.275 |
|
| 2002 |
Sun H, Bapu Reddy G, George C, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. Synthesis and biological activity of 3-hydroxy(phosphono)methyl-bearing phosphatidylinositol ether lipid analogues Tetrahedron Letters. 43: 2835-2838. DOI: 10.1016/S0040-4039(02)00354-4 |
0.275 |
|
| 1977 |
Powis G, Lyon L, McKillop D. Nadh synergism of microsomal aniline metabolism in the presence of enhancing agents Biochemical Pharmacology. 26: 137-141. PMID 13799 DOI: 10.1016/0006-2952(77)90386-0 |
0.275 |
|
| 1990 |
Seewald MJ, Olsen RA, Powis G. Suramin blocks intracellular Ca2+ release and growth factor-induced increases in cytoplasmic free Ca2+ concentration. Cancer Letters. 49: 107-13. PMID 2306703 DOI: 10.1016/0304-3835(90)90145-N |
0.273 |
|
| 2005 |
Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Molecular Cancer Therapeutics. 4: 1349-57. PMID 16170026 DOI: 10.1158/1535-7163.Mct-05-0149 |
0.273 |
|
| 1998 |
Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Dorr R, Dvorakova K, Salmon S, Harrison S, Worzalla J. Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. Cancer Chemotherapy and Pharmacology. 41: 22-8. PMID 9443610 DOI: 10.1007/S002800050703 |
0.273 |
|
| 2011 |
Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA. Development of sulfonamide AKT PH domain inhibitors. Bioorganic & Medicinal Chemistry. 19: 2046-54. PMID 21353784 DOI: 10.1016/J.Bmc.2011.01.049 |
0.273 |
|
| 2004 |
McNaughton M, Engman L, Birmingham A, Powis G, Cotgreave IA. Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth. Journal of Medicinal Chemistry. 47: 233-9. PMID 14695837 DOI: 10.1021/Jm030916R |
0.268 |
|
| 1990 |
Kozikowski AP, Fauq AH, Powis G, Melder DC. Efficient synthetic routes in fluorinated isosteres of inositol and their effects on cellular growth Journal of the American Chemical Society. 112: 4528-4531. DOI: 10.1021/Ja00167A061 |
0.268 |
|
| 2015 |
James BP, Lemos R, Bagby S, Robinson S, Robinson W, Tentler J, Eckhardt SG, Kirkpatrick DL, Powis G. Abstract A2-29: A PDK1 inhibitors that has antitumor activity in a vemurafenib resistant BRAF(V600E)::NRAS(G12V) melanoma PDX Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A2-29 |
0.268 |
|
| 2004 |
Wipf P, Lynch SM, Birmingham A, Tamayo G, Jiménez A, Campos N, Powis G. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. Organic & Biomolecular Chemistry. 2: 1651-8. PMID 15162219 DOI: 10.1039/B402431A |
0.267 |
|
| 1992 |
Powis G, Aksoy IA, Melder DC, Aksoy S, Eichinger H, Fauq AH, Kozikowski AP. D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth. Cancer Chemotherapy and Pharmacology. 29: 95-104. PMID 1760864 DOI: 10.1007/BF00687317 |
0.262 |
|
| 1994 |
Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Grindey GB, Bonjouklian R. Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues. Cancer Chemotherapy and Pharmacology. 34: 344-50. PMID 8033301 DOI: 10.1007/Bf00686043 |
0.262 |
|
| 2014 |
Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Molecular Cancer Therapeutics. 13: 3074-85. PMID 25344581 DOI: 10.1158/1535-7163.MCT-13-1001 |
0.261 |
|
| 2011 |
Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro-Oncology. 13: 367-75. PMID 21430111 DOI: 10.1093/neuonc/nor012 |
0.26 |
|
| 2020 |
Cho EJ, Devkota AK, Stancu G, Edupunganti R, Debevec G, Giulianotti M, Houghten R, Powis G, Dalby KN. A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase A. Slas Discovery : Advancing Life Sciences R & D. 2472555220926146. PMID 32462959 DOI: 10.1177/2472555220926146 |
0.259 |
|
| 1995 |
Powis G, Alberts DS. Inhibiting intracellular signalling as a strategy for cancer chemoprevention. European Journal of Cancer (Oxford, England : 1990). 1138-44. PMID 7654446 DOI: 10.1016/0959-8049(94)90473-1 |
0.257 |
|
| 2009 |
Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Molecular Cancer Therapeutics. 8: 94-100. PMID 19139117 DOI: 10.1158/1535-7163.Mct-08-0714 |
0.255 |
|
| 1977 |
Powis G, Jansson I, Schenkman JB. The effects of albumin upon the spectral changes and metabolism by the hepatic microsomal fraction. Archives of Biochemistry and Biophysics. 179: 34-42. PMID 843088 DOI: 10.1016/0003-9861(77)90083-2 |
0.251 |
|
| 1994 |
Oblong JE, Chantler EL, Gallegos A, Lyn Kirkpatrick D, Chen T, Marshall N, Powis G. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues Cancer Chemotherapy and Pharmacology. 34: 434-438. DOI: 10.1007/BF00685570 |
0.249 |
|
| 1976 |
Powis G, Grant L. The effect of inhibitors of alcohol metabolism upon the changes in the hepatic microsomal metabolism of foreign compounds produced by the acute administration of some alcohols to the rat Biochemical Pharmacology. 25: 2197-2201. PMID 971332 DOI: 10.1016/0006-2952(76)90132-5 |
0.247 |
|
| 2009 |
Bartholomeusz G, Cherukuri P, Kingston J, Cognet L, Lemos R, Leeuw TK, Gumbiner-Russo L, Weisman RB, Powis G. In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA. Nano Research. 2: 279-291. PMID 20052401 DOI: 10.1007/S12274-009-9026-7 |
0.247 |
|
| 1975 |
Powis G, Boobis AR. The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents. Biochemical Pharmacology. 24: 424-426. PMID 1125053 DOI: 10.1016/0006-2952(75)90230-0 |
0.245 |
|
| 2010 |
Schwartz DL, Bankson JA, Lemos R, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Molecular Cancer Therapeutics. 9: 2057-67. PMID 20587661 DOI: 10.1158/1535-7163.Mct-09-0768 |
0.241 |
|
| 1992 |
Powis G, Seewald MJ, Melder D, Hoke M, Gratas C, Christensen TA, Chapman DE. Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin. Cancer Chemotherapy and Pharmacology. 31: 223-8. PMID 1464160 DOI: 10.1007/BF00685552 |
0.24 |
|
| 2010 |
Koh MY, Spivak-Kroizman TR, Powis G. HIF-1alpha and cancer therapy. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 180: 15-34. PMID 20033376 DOI: 10.1007/978-3-540-78281-0_3 |
0.239 |
|
| 2009 |
Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorganic & Medicinal Chemistry. 17: 6983-92. PMID 19734051 DOI: 10.1016/J.Bmc.2009.08.022 |
0.238 |
|
| 2011 |
Koh MY, Lemos R, Liu X, Powis G. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Research. 71: 4015-27. PMID 21512133 DOI: 10.1158/0008-5472.CAN-10-4142 |
0.235 |
|
| 2019 |
Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, ... ... Powis G, et al. Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. Cancer Research. 79: 5457. PMID 31615811 DOI: 10.1158/0008-5472.Can-19-2586 |
0.234 |
|
| 2019 |
Poreba M, Groborz K, Vizovisek M, Maruggi M, Turk D, Turk B, Powis G, Drag M, Salvesen GS. Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples. Chemical Science. 10: 8461-8477. PMID 31803426 DOI: 10.1039/C9Sc00997C |
0.23 |
|
| 2016 |
de Jong PR, Taniguchi K, Harris AR, Bertin S, Takahashi N, Duong J, Campos AD, Powis G, Corr M, Karin M, Raz E. ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation. Nature Communications. 7: 11551. PMID 27187615 DOI: 10.1038/ncomms11551 |
0.229 |
|
| 2013 |
Sun D, Bhanu Prasad BA, Schuber PT, Peng Z, Maxwell DS, Martin DV, Guo L, Han D, Kurihara H, Yang DJ, Gelovani JG, Powis G, Bornmann WG. Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase. Bioorganic & Medicinal Chemistry. 21: 5182-7. PMID 23859776 DOI: 10.1016/J.Bmc.2013.06.036 |
0.229 |
|
| 1974 |
Boobis AR, Powis G. The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat. Biochemical Pharmacology. 23: 3377-3384. PMID 4374219 DOI: 10.1016/0006-2952(74)90340-2 |
0.228 |
|
| 2016 |
Tchoghandjian A, Koh MY, Taieb D, Ganaha S, Powis G, Bialecki E, Graziani N, Figarella-Branger D, Metellus P. Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome. Oncotarget. PMID 26989023 DOI: 10.18632/Oncotarget.8046 |
0.227 |
|
| 2011 |
Ihle NT, Powis G, Kopetz S. PI-3-Kinase inhibitors in colorectal cancer. Current Cancer Drug Targets. 11: 190-8. PMID 21158718 DOI: 10.2174/156800911794328448 |
0.225 |
|
| 1986 |
Appel PL, Alley MC, Lieber MM, Shoemaker R, Powis G. Metabolic stability of experimental chemotherapeutic agents in hepatocyte:tumor cell co-cultures. Cancer Chemotherapy and Pharmacology. 17: 47-52. PMID 3698177 DOI: 10.1007/BF00299865 |
0.224 |
|
| 1987 |
Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmacology & Therapeutics. 35: 57-162. PMID 3321102 DOI: 10.1016/0163-7258(87)90105-7 |
0.224 |
|
| 2009 |
Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Molecular Cancer Therapeutics. 8: 1-9. PMID 19139107 DOI: 10.1158/1535-7163.MCT-08-0801 |
0.222 |
|
| 2008 |
Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 36: 178-86. PMID 18376310 DOI: 10.1097/MPA.0b013e31815929fe |
0.219 |
|
| 2016 |
Kirkpatrick DL, Powis G. Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling. Antioxidants & Redox Signaling. PMID 26983373 DOI: 10.1089/ars.2016.6633 |
0.219 |
|
| 2010 |
Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 940-9. PMID 20512076 DOI: 10.1097/JTO.0b013e3181dc211f |
0.216 |
|
| 1989 |
Olsen R, Seewald M, Powis G. Contribution of external and internal Ca2+ to changes in intracellular free Ca2+ produced by mitogens in Swiss 3T3 fibroblasts: the role of dihydropyridine sensitive Ca2+ channels. Biochemical and Biophysical Research Communications. 162: 448-55. PMID 2473747 DOI: 10.1016/0006-291X(89)92018-4 |
0.214 |
|
| 2013 |
Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 657-67. PMID 23251002 DOI: 10.1158/1078-0432.Ccr-11-1446 |
0.211 |
|
| 2010 |
Ihle NT, Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Molecular Aspects of Medicine. 31: 135-44. PMID 20176047 DOI: 10.1016/j.mam.2010.02.003 |
0.211 |
|
| 2016 |
Koh MY, Gagea M, Sargis T, Lemos R, Grandjean G, Charbono A, Bekiaris V, Sedy J, Kiriakova G, Liu X, Roberts LR, Ware C, Powis G. A new HIF-1α/RANTES driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF. Hepatology (Baltimore, Md.). PMID 26799785 DOI: 10.1002/hep.28468 |
0.211 |
|
| 2012 |
Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N. Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Translational Oncology. 5: 190-9. PMID 22741038 DOI: 10.1593/Tlo.11322 |
0.21 |
|
| 2009 |
Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Research. 69: 143-50. PMID 19117997 DOI: 10.1158/0008-5472.Can-07-6656 |
0.208 |
|
| 2011 |
Schwartz DL, Bankson J, Bidaut L, He Y, Williams R, Lemos R, Thitai AK, Oh J, Volgin A, Soghomonyan S, Yeh HH, Nishii R, Mukhopadhay U, Alauddin M, Mushkudiani I, ... ... Powis G, et al. HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Molecular Cancer Research : McR. 9: 259-70. PMID 21364021 DOI: 10.1158/1541-7786.Mcr-10-0469 |
0.208 |
|
| 2016 |
Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. Bmc Cancer. 16: 200. PMID 26955870 DOI: 10.1186/s12885-016-2232-2 |
0.204 |
|
| 2010 |
Ihle NT, Powis G. The biological effects of isoform-specific PI3-kinase inhibition. Current Opinion in Drug Discovery & Development. 13: 41-9. PMID 20047145 |
0.204 |
|
| 1980 |
Moore ED, Powis G. Plasma and tissue concentrations of hycanthone in the mouse determined by reversed-phase high-performance liquid chromatography. Journal of Chromatography. 183: 372-7. PMID 7419657 DOI: 10.1016/S0378-4347(00)81720-X |
0.203 |
|
| 2014 |
Kirkpatrick L, Triana-Baltzer G, Indarte M, Scott M, Lemos R, Powis G. 490 Potent and selective inhibitors of the KRAS-signaling nanocluster protein, CNKSR1, block oncogenic KRAS signaling and mut-KRAS cell growth European Journal of Cancer. 50: 160. DOI: 10.1016/S0959-8049(14)70616-1 |
0.202 |
|
| 1992 |
Powis G, Seewald M, Hoke M. Inhibition of growth factor binding and intracellular Ca2+ signalling by dextran sulfates of different sizes and degrees of sulfation. Cancer Chemotherapy and Pharmacology. 30: 483-6. PMID 1394806 DOI: 10.1007/BF00685602 |
0.2 |
|
| 2011 |
Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S. Recent development of anticancer therapeutics targeting Akt. Recent Patents On Anti-Cancer Drug Discovery. 6: 146-59. PMID 21110830 DOI: 10.2174/157489211793980079 |
0.2 |
|
| 2006 |
Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemotherapy and Pharmacology. 58: 444-50. PMID 16485116 DOI: 10.1007/s00280-006-0190-0 |
0.2 |
|
| 1990 |
Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. International Journal of Cancer. 45: 403-9. PMID 2307529 DOI: 10.1002/IJC.2910450304 |
0.2 |
|
| 2008 |
Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics. 7: 90-100. PMID 18202012 DOI: 10.1158/1535-7163.MCT-07-0463 |
0.199 |
|
| 2005 |
Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G, Baker AF. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 529-36. PMID 15701837 |
0.197 |
|
| 1988 |
Brodfüehrer JI, Moore DJ, Melder DC, Wilke TJ, Powis G. In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation. Investigational New Drugs. 6: 3-9. PMID 3410664 DOI: 10.1007/BF00170773 |
0.197 |
|
| 1994 |
Powis G, Phil D. Inhibitors of phosphatidylinositol signalling as antiproliferative agents. Cancer Metastasis Reviews. 13: 91-103. PMID 8143348 DOI: 10.1007/BF00690420 |
0.196 |
|
| 1980 |
Powis G, Jansson I. Stoichiometry of the mixed function oxidase. Pharmacology & Therapeutics. 7: 297-311. PMID 42935 DOI: 10.1016/0163-7258(79)90033-0 |
0.19 |
|
| 2008 |
Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. Plos One. 3: e2220. PMID 18493606 DOI: 10.1371/Journal.Pone.0002220 |
0.19 |
|
| 2004 |
Kirkpatrick L, Powis G, Ihle N, Paine-Murrieta G, Minion D, Halter R, Abraham R, Wipf P. 248 Antitumor activity, pharmacodynamics and toxicity of PX-866 a novel inhibitor of phosphoinositide-3-kinase European Journal of Cancer Supplements. 2: 77. DOI: 10.1016/s1359-6349(04)80256-8 |
0.19 |
|
| 1994 |
Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 91: 4673-7. PMID 8197117 DOI: 10.1073/PNAS.91.11.4673 |
0.19 |
|
| 2017 |
Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, ... ... Powis G, et al. Modeling of Patient Derived Xenografts in Colorectal Cancer. Molecular Cancer Therapeutics. PMID 28468778 DOI: 10.1158/1535-7163.Mct-16-0721 |
0.19 |
|
| 1996 |
Powis G. Anticancer drugs acting against signaling pathways. Current Opinion in Oncology. 7: 554-9. PMID 8547405 DOI: 10.1097/00001622-199511000-00014 |
0.186 |
|
| 2008 |
Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends in Biochemical Sciences. 33: 526-34. PMID 18809331 DOI: 10.1016/j.tibs.2008.08.002 |
0.182 |
|
| 2008 |
Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Molecular and Cellular Biology. 28: 7081-95. PMID 18838541 DOI: 10.1128/MCB.00773-08 |
0.181 |
|
| 2015 |
Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma Cancer Research. 75: 316-329. DOI: 10.1158/0008-5472.CAN-13-2190 |
0.179 |
|
| 2012 |
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, ... ... Powis G, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. Journal of the National Cancer Institute. 104: 228-39. PMID 22247021 DOI: 10.1093/jnci/djr523 |
0.179 |
|
| 1988 |
Schlager JJ, Powis G. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase. Cancer Chemotherapy and Pharmacology. 22: 126-30. PMID 3136941 DOI: 10.1007/BF00257309 |
0.177 |
|
| 2017 |
Cho EJ, Devkota AK, Stancu G, Edupunganti R, Powis G, Dalby KN. A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase. Slas Discovery. 2472555217726325. PMID 28820953 DOI: 10.1177/2472555217726325 |
0.175 |
|
| 2012 |
Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5160-2. PMID 22912394 DOI: 10.1158/1078-0432.CCR-12-2408 |
0.173 |
|
| 2012 |
Lemos R, Kopetz S, Jiang Z, Dasari A, Maru D, Powis G. 61 Patient-derived Metastatic Colorectal Cancer Mouse Tumorgrafts for Anticancer and Mechanism Studies European Journal of Cancer. 48: 20-21. DOI: 10.1016/S0959-8049(12)71859-2 |
0.171 |
|
| 1992 |
Kozikowski AP, Fauq AH, Powis G, Kurian P, Crews FT. Expedient synthetic routes to [3H]-D-3-azido-3-deoxy-myo- inositol and D-3-azido-3-deoxy-myo-inositol 2,4,5-trisphosphate Journal of the Chemical Society, Chemical Communications. 362-364. DOI: 10.1039/C39920000362 |
0.169 |
|
| 2012 |
Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, Kim H, Li M, Downey TJ, Dyer MD, Sun Y, Sun J, Beasley EM, Chung HC, Noh SH, ... ... Powis G, et al. AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Research. 72: 2512-21. PMID 22434430 DOI: 10.1158/0008-5472.CAN-11-3870 |
0.169 |
|
| 1997 |
Powis G, Gasdaska JR, Baker A. Redox signaling and the control of cell growth and death. Advances in Pharmacology (San Diego, Calif.). 38: 329-59. PMID 8895815 DOI: 10.1016/S1054-3589(08)60990-4 |
0.169 |
|
| 2023 |
Powis G, Meuillet EJ, Indarte M, Booher G, Kirkpatrick L. Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 165: 115024. PMID 37399719 DOI: 10.1016/j.biopha.2023.115024 |
0.164 |
|
| 1995 |
Gasdaska PY, Gasdaska JR, Cochran S, Powis G. Cloning and sequencing of a human thioredoxin reductase. Febs Letters. 373: 5-9. PMID 7589432 DOI: 10.1016/0014-5793(95)01003-W |
0.162 |
|
| 2006 |
Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2964-6. PMID 16707590 DOI: 10.1158/1078-0432.CCR-06-0617 |
0.161 |
|
| 2015 |
Morris VK, James B, Tian F, Jiang Z, Overman MJ, Maru DM, Menter D, Powis G, Kopetz S. Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: 629-629. DOI: 10.1200/Jco.2015.33.3_Suppl.629 |
0.16 |
|
| 1989 |
Chapman DE, Moore DJ, Melder DC, Breau A, Powis G. Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma. Cancer Chemotherapy and Pharmacology. 25: 184-8. PMID 2598409 DOI: 10.1007/BF00689580 |
0.158 |
|
| 2005 |
Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4338-40. PMID 15958615 DOI: 10.1158/1078-0432.CCR-05-0422 |
0.156 |
|
| 1998 |
Grunicke HH, Powis G. Cell signalling and cancer treatment. AACR special conference in cancer research in collaboration with the British Association for Cancer Research, the German Cancer Society (Section for Experimental Cancer Research), the Austrian Biochemical Society, and the Austrian Cancer Society. 23-28 February 1997, Telfs-Buchen, Austria. Journal of Cancer Research and Clinical Oncology. 124: 462-9. PMID 9750024 DOI: 10.1007/s004320050200 |
0.155 |
|
| 2000 |
Payne CM, Holubec H, Bernstein H, Bernstein C, Warneke JA, Powis G, Garewal H. Aberrant expression of NF-KB, NOS2 and tidoredoxin in the normal-appearing flat mucosa of patients with colonic neoplasia Gastroenterology. 118: A281. DOI: 10.1016/S0016-5085(00)83209-6 |
0.155 |
|
| 2021 |
Aleshin AE, Yao Y, Iftikhar A, Bobkov AA, Yu J, Cadwell G, Klein MG, Dong C, Bankston LA, Liddington RC, Im W, Powis G, Marassi FM. Structural basis for the association of PLEKHA7 with membrane-embedded phosphatidylinositol lipids. Structure (London, England : 1993). PMID 33878292 DOI: 10.1016/j.str.2021.03.018 |
0.151 |
|
| 2004 |
List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Experimental Hematology. 32: 526-35. PMID 15183893 DOI: 10.1016/J.Exphem.2004.03.005 |
0.149 |
|
| 2010 |
Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA. IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Experimental Dermatology. 19: 714-22. PMID 20545760 DOI: 10.1111/J.1600-0625.2010.01077.X |
0.148 |
|
| 2015 |
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JJ, Gibbs P, James B, Powis G, Nolop KB, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26460303 DOI: 10.1200/JCO.2015.63.2497 |
0.145 |
|
| 1994 |
Powis G. Recent Advances in the Development of Anticancer Drugs that Act against Signalling Pathways Tumori Journal. 80: 69-87. DOI: 10.1177/030089169408000201 |
0.144 |
|
| 2010 |
POWIS G, HILL SR, FREW TJ, SHERRILL KW. ChemInform Abstract: Inhibitors of Phospholipid Intracellular Signaling as Antiproliferative Agents Cheminform. 26: no-no. DOI: 10.1002/CHIN.199531308 |
0.14 |
|
| 2012 |
Ihle N, Abdelmelek M, Zhang S, Indarte M, Kirkpatrick D, Powis G. 406 PHT-782 an Inhibitor of the KRAS Signaling Nanocluster Protein CNKSR1 Blocks Oncogenic KRAS Signaling European Journal of Cancer. 48: 123-124. DOI: 10.1016/S0959-8049(12)72204-9 |
0.13 |
|
| 2013 |
Papadimitrakopoulou V, Wistuba II, Lee JJ, Tsao AS, Kalhor N, Fossella FV, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, ... Powis G, et al. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: TPS8118-TPS8118. DOI: 10.1200/JCO.2013.31.15_SUPPL.TPS8118 |
0.125 |
|
| 1991 |
Olsen RA, Seewald MJ, Melder DC, Berggren M, Iaizzo PA, Powis G. Platelet-derived growth factor blocks the increase in intracellular free Ca2+ caused by calcium ionophores and a volatile anesthetic agent in Swiss 3T3 fibroblasts without altering toxicity. Toxicology Letters. 55: 117-25. PMID 1998194 DOI: 10.1016/0378-4274(91)90033-3 |
0.121 |
|
| 2006 |
Schwartz D, Krishnan S, Kuno N, Mushkudiani I, Volgin A, Yeh H, He Y, Soghomonyan S, Powis G, Gelovani J. 84 International Journal of Radiation Oncology*Biology*Physics. 66: S49. DOI: 10.1016/J.IJROBP.2006.07.114 |
0.12 |
|
| 2000 |
Hu Y, Meuillet EJ, Qiao L, Berggren MM, Powis G, Kozikowski AP. Synthesis and Akt inhibitory properties of a 1D-3,4-dideoxyphosphatidylinositol ether lipid Tetrahedron Letters. 41: 7415-7418. DOI: 10.1016/S0040-4039(00)01186-2 |
0.118 |
|
| 1974 |
Powis G. Binding of catecholamines to connective tissue and the effect upon the responses of blood vessels to noradrenaline and to nerve stimulation. The Journal of Physiology. 234: 145-62. PMID 4766218 DOI: 10.1113/jphysiol.1973.sp010339 |
0.116 |
|
| 2009 |
Koh MY, Powis G. HAF : the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle (Georgetown, Tex.). 8: 1359-66. PMID 19377289 DOI: 10.4161/cc.8.9.8303 |
0.113 |
|
| 1990 |
Iaizzo PA, Olsen RA, Seewald MJ, Powis G, Stier A, Van Dyke RA. Transient increases of intracellular Ca2+ induced by volatile anesthetics in rat hepatocytes. Cell Calcium. 11: 515-24. PMID 2265428 DOI: 10.1016/0143-4160(90)90027-R |
0.11 |
|
| 2006 |
Powis G. Achieving personalized cancer medicine: trials and tribulations. Journal of Investigative Medicine : the Official Publication of the American Federation For Clinical Research. 54: 235-7. PMID 16984795 DOI: 10.2310/6650.2006.06026 |
0.107 |
|
| 1981 |
Letendre L, Smithson WA, Gilchrist GS, Burgert EO, Hoagland CH, Ames MM, Powis G, Kovach JS. Activity of indicine N-oxide in refractory acute leukemia. Cancer. 47: 437-41. PMID 7013959 DOI: 10.1002/1097-0142(19810201)47:3<437::AID-CNCR2820470303>3.0.CO;2-R |
0.104 |
|
| 2012 |
Powis G, Ihle N, Kirkpatrick D. 7 KRAS the Elephant in the Room of Cancer Therapy: New Approaches European Journal of Cancer. 48: 7. DOI: 10.1016/S0959-8049(12)71806-3 |
0.104 |
|
| 1993 |
Chapman DE, Michener SR, Powis G. In vitro metabolism of [3H]2,6-dinitrotoluene by human and rat liver Toxicology in Vitro. 7: 213-220. DOI: 10.1016/0887-2333(93)90003-N |
0.104 |
|
| 2006 |
Culotta K, Kirkpatrick D, Covey J, Schultz C, Mack D, Rhea R, Allen T, Powis G, Johansen M, Madden T. 434 POSTER Preclinical pharmacokinetic and comparative biodistribution studies of PX-866, a broad spectrum phosphatidylinositol-3-kinase (Pl-3K) Inhibitor, in F344 rats European Journal of Cancer Supplements. 4: 132. DOI: 10.1016/S1359-6349(06)70439-6 |
0.101 |
|
| 1990 |
Olsen R, Melder D, Seewald M, Abraham R, Powis G. Staurosporine inhibition of intracellular free Ca2+ transients in mitogen-stimulated Swiss 3T3 fibroblasts. Biochemical Pharmacology. 39: 968-72. PMID 2310422 DOI: 10.1016/0006-2952(90)90216-8 |
0.094 |
|
| 2009 |
Powis G, Ihle NT, Yung WK. Inhibiting PI-3-K for glioma therapy. Cell Cycle (Georgetown, Tex.). 8: 335. PMID 19164951 |
0.094 |
|
| 1988 |
Brodfuehrer JI, Powis G. Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma. Journal of Chromatography. 427: 247-55. PMID 3410909 DOI: 10.1016/0378-4347(88)80127-0 |
0.089 |
|
| 2011 |
Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ. Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. Radiation Research. 176: e0016-21. PMID 21867428 DOI: 10.1667/Rrol02.1 |
0.088 |
|
| 2011 |
Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ. Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities: Report of an NCI Workshop held September 1-3, 2010. Radiation Research. PMID 21740251 DOI: 10.1667/RROL02.1 |
0.088 |
|
| 2010 |
FAUQ AH, KOZIKOWSKI AP, GALLEGOS A, POWIS G. ChemInform Abstract: Total Synthesis of 3-Chloro-3-deoxy-1-O-(1,2-di-O-palmitoyl-sn-glycero- 3-phospho)-D-myo-inositol. A Potential Mechanistic Probe for Phosphoinositide Signal Transduction Pathways. Cheminform. 25: no-no. DOI: 10.1002/CHIN.199414287 |
0.088 |
|
| 1998 |
Peng H, Zalkow LH, Abraham RT, Powis G. Novel CDC25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. Journal of Medicinal Chemistry. 41: 4677-80. PMID 9822537 DOI: 10.1021/jm980500r |
0.086 |
|
| 1988 |
Southorn PA, Powis G. Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clinic Proceedings. 63: 381-9. PMID 2832662 DOI: 10.1016/S0025-6196(12)64861-7 |
0.086 |
|
| 2010 |
SEEWALD MJ, AKSOY IA, POWIS G, FAUQ AH, KOZIKOWSKI AP. ChemInform Abstract: Synthesis of D-3-Deoxy-myo-inositol 1,4,5-Triphosphate and Its Effect of Ca2+ Release in NIH 3T3 Cells. Cheminform. 22: no-no. DOI: 10.1002/CHIN.199117279 |
0.085 |
|
| 1993 |
Iaizzo PA, Seewald MJ, Powis G, Van Dyke RA. The effects of sevoflurane on intracellular Ca2+ regulation in rat hepatocytes. Toxicology Letters. 66: 81-8. PMID 8427024 DOI: 10.1016/0378-4274(93)90082-9 |
0.084 |
|
| 2011 |
Momin AA, James BP, Motter TC, Kadara HN, Powis G, Wistuba II. Integrating whole transcriptome sequence data and public databases for analysis of somatic mutations in tumors Genome Biology. 12: P44. DOI: 10.1186/gb-2011-12-s1-p44 |
0.083 |
|
| 1991 |
Chapman DE, Michener SR, Powis G. Metabolism of the flame retardant plasticizer tris(2-chloroethyl)phosphate by human and rat liver preparations. Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology. 17: 215-24. PMID 1765216 DOI: 10.1093/toxsci/17.2.215 |
0.082 |
|
| 1994 |
Workman P, D'Incalci M, Bursch W, Harrap KR, Hawkins RE, Neidle S, Powis G. European school of oncology task force report. New approaches in cancer pharmacology: Drug design and development (Part 2) European Journal of Cancer Part a: General Topics. 30: 1148-1160. PMID 7654448 DOI: 10.1016/0959-8049(94)90475-8 |
0.081 |
|
| 1988 |
Southorn PA, Powis G. Free radicals in medicine. II. Involvement in human disease. Mayo Clinic Proceedings. 63: 390-408. PMID 3280885 DOI: 10.1016/S0025-6196(12)64862-9 |
0.081 |
|
| 1989 |
Workman P, Walton MI, Powis G, Schlager JJ. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? British Journal of Cancer. 60: 800-2; discussion 80. PMID 2508739 DOI: 10.1038/bjc.1989.364 |
0.073 |
|
| 1990 |
Kozikowski AP, Fauq AH, Aksoy IA, Seewald MJ, Powis G. Synthesis of the first optically pure, fluorinated inositol 1,4,5-trisphosphate of myo-inositol. Stereochemistry and its effect on calcium(2+) release in Swiss 3T3 cells Journal of the American Chemical Society. 112: 7403-7404. DOI: 10.1021/JA00176A055 |
0.071 |
|
| 1990 |
Iaizzo PA, Seewald MJ, Powis G, Van Dyke RA. The effects of volatile anesthetics on Ca++ mobilization in rat hepatocytes. Anesthesiology. 72: 504-9. PMID 2310032 DOI: 10.1097/00000542-199003000-00019 |
0.069 |
|
| 1995 |
Powis G, Abraham RT, Ashendel CL, Zalkow LH, Grindey GB, Vlahos CJ, Merriman R, Bonjouklian R. Anticancer Drugs and Signalling Targets: Principles and Examples International Journal of Pharmacognosy. 33: 17-26. DOI: 10.3109/13880209509067084 |
0.066 |
|
| 1993 |
Powis G, Hacker MP, Carlon GC. The Toxicity of Anticancer Drugs Critical Care Medicine. 21: 1101. DOI: 10.1097/00003246-199307000-00034 |
0.063 |
|
| 1991 |
Iaizzo PA, Seewald MJ, Olsen R, Wedel DJ, Chapman DE, Berggren M, Eichinger HM, Powis G. Enhanced mobilization of intracellular Ca2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia. Anesthesiology. 74: 531-8. PMID 2001032 DOI: 10.1097/00000542-199103000-00023 |
0.063 |
|
| 2000 |
Qiao L, Hu Y, Nan F, Powis G, Kozikowski AP. A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-Quebrachitol Organic Letters. 2: 115-117. PMID 10814260 DOI: 10.1021/OL991188Y |
0.053 |
|
| 1992 |
Kozikowski AP, Tückmantel W, Powis G. Synthese und biologische Aktivität vonD-3-Desoxy-3-fluorphosphatidylinosit, ein neuer Weg zu nicht auf DNA zielenden Cytostatica Angewandte Chemie. 104: 1408-1410. DOI: 10.1002/ANGE.19921041032 |
0.052 |
|
| Hide low-probability matches. |